机构：[1]Lung Cancer Center, West China Hospital Sichuan University Chengdu China.四川大学华西医院[2]School of Dentistry, Department of Pathology University of California Los Angeles California USA.[3]Department of Biostatistics, MD Anderson Cancer Center University of Texas Houston Texas USA.[4]Department of Thoracic Surgery, Henan Cancer Hospital University of Zhengzhou Zhengzhou China.河南省肿瘤医院[5]Department of Thoracic Surgery, Jiangsu Cancer Hospital Nanjing Medical University Nanjing China.[6]Laboratory of Lung Development and Disease West China Second University Hospital, Sichuan University Chengdu China.[7]Department of Cancer Epidemiology Cancer Hospital/Institute, Chinese Academy of Medical Sciences Beijing China.
This article describes a pilot study evaluating a novel liquid biopsy system for non-small cell lung cancer (NSCLC) patients. The electric field-induced release and measurement (EFIRM) method utilizes an electrochemical biosensor for detecting oncogenic mutations in biofluids.
Saliva and plasma of 17 patients were collected from three cancer centers prior to and after surgical resection. The EFIRM method was then applied to the collected samples to assay for exon 19 deletion and p.L858 mutations. EFIRM results were compared with cobas results of exon 19 deletion and p.L858 mutation detection in cancer tissues.
The EFIRM method was found to detect exon 19 deletion with an area under the curve (AUC) of 1.0 in both saliva and plasma samples in lung cancer patients. For L858R mutation detection, the AUC of saliva was 1.0, while the AUC of plasma was 0.98. Strong correlations were also found between presurgery and post-surgery samples for both saliva (0.86 for exon 19 and 0.98 for L858R) and plasma (0.73 for exon 19 and 0.94 for L858R).
Our study demonstrates the feasibility of utilizing EFIRM to rapidly, non-invasively, and conveniently detect epidermal growth factor receptor mutations in the saliva of patients with NSCLC, with results corresponding perfectly with the results of cobas tissue genotyping.
基金：
This work was partly supported by grants from the
National “863” Major Project of China (No.
2012AA02A201 and No. 2012AA02A502), the National
Natural Science Foundation of China (No. 81572288) and the Ministry of Education Fund Priority to the Development
of Instructions of Higher Leading Doctoral Degree
Field (No. 20131202130001).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类|4 区医学
小类|4 区肿瘤学4 区呼吸系统
最新[2023]版：
大类|3 区医学
小类|4 区肿瘤学4 区呼吸系统
第一作者：
第一作者机构：[1]Lung Cancer Center, West China Hospital Sichuan University Chengdu China.
共同第一作者：
通讯作者：
通讯机构：[1]Lung Cancer Center, West China Hospital Sichuan University Chengdu China.[2]School of Dentistry, Department of Pathology University of California Los Angeles California USA.[*1]Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.[*2]School of Dentistry, Center for Oral/Head & Neck Oncology Research, University of California Los Angeles, 10833 Le Conte Avenue, 73-034 CHS, Los Angeles, CA 90095, USA.
推荐引用方式(GB/T 7714)：
Pu Dan,Liang Hao,Wei Fang,et al.Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study.[J].Thoracic cancer.2016,7(4):428-36.doi:10.1111/1759-7714.12350.
APA：
Pu Dan,Liang Hao,Wei Fang,Akin David,Feng Ziding...&Zhou Qinghua.(2016).Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study..Thoracic cancer,7,(4)
MLA：
Pu Dan,et al."Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study.".Thoracic cancer 7..4(2016):428-36
